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ARTICLE INFO                                         ABSTRACT 
 
 
 
 
Rabbit syndrome (RS) is an involuntary movement disorder, characterized by fast and fine 
movements of oral and masticatory muscles along the mouth vertical axis in the absence of tongue 
involvement. RS prevalence varies between 2.3% to 4.4% and could result from the administration of 
antipsychotics and antidepressants. In case of second generation antipsychotics, there is a reduced risk 
of RS compared with first generation antipsychotics with mainly isolated literature case reports 
especially with the use of risperidone as antipsychotic. RS affects only the buccal region, with the 
possible involvement of the basal ganglia, in particular the substantia nigra.  The management of RS 
include reduction or change of the psychotropic treatment and use of anticholinergic medications such 
as trihexyphenidyl. Although RS is rare and easily treatable, it is essential that dentists and 
psychiatrists could distinguish this syndrome from other movement disorders such as tardive 
dyskinesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2019 Ayman Antoun Reyad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
 
 
 
 
INTRODUCTION 
 
Rabbit syndrome (RS) is a vertical rhythmic dyskinesia of the 
mouth and lips with no tongue involvement. This involuntary 
movement disorder is characterized by fast and fine 
movements of oral and masticatory muscles along the vertical 
axis of the mouth, similar to chewing movements of a rabbit at 
a frequency of approximately 5 Hz (1). Fatigue, anxiety, 
attention, concentration, motor performances and stressful 
situations could intensify RS symptoms with an increase in 
muscle tone (2). RS is often misdiagnosed as tardive 
dyskinesia, the tongue-involving movement disorder (3), 
where the movements of the mouth are less regular and slower 
and involve the tongue (4).RS symptoms could be presented as 
the outcome of antipsychotics and/or antidepressants side 
effects, which are related to extrapyramidal side effects 
(EPSE). These well-known antipsychotics side effects are due 
mainly to the antipsychotic antagonist activity on the 
dopaminergic receptors (5). 
 
In this review article, we describe RS clinical manifestations 
and prevalence, while focussing on the associated medications 
pharmacology and commenting on the literature clinical cases 
with discussion on the current management options. 
 
Rabbit Syndrome and Antipsychotics 
 
Rabbit syndrome is considered a rare side effect of prolonged 
antipsychotics treatment. Its involuntary movements could 
appear after prolonged treatment (months or years); however, 
in few cases absence of antipsychotic involvement was 
demonstrated. RS reported prevalence varies between 2.3% to 
4.4% of patients managed with first generation antipsychotics 
(FGA) with elderly, female gender and previous brain injuries 
considered risk factors (4) as highlighted in a study following 
266 chronic inpatients receiving antipsychotics, where 
4.4%suffered RS, while co-administering anticholinergic 
medications such as procyclidine resulted in resolving RS 
signs/symptoms (6). 
 
For second generation antipsychotics (SGA), there is a reduced 
risk of RS with mainly isolated case reports in literature (7)for 
amisulpiride, risperidone, levosulpiride and paliperidone as 
potential culprit for RS especially risperidone (8-14) such as 
the case of 38-year-old man with a major depressive disorder 
on 4 month treatment of risperidone, where RS responded to 
anticholinergic treatment (15). Although olanzapine and 
clozapine are antipsychotics with less risk of EPSE, RS was 
reported (16-18).In paediatric population, some reports of RS 
following antipsychotic administration were also reported (19) 
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such as a bipolar patient, who suffered RS signs/symptoms 
following quetiapine administration (20,21). Some clinical 
cases were also reported for RS as a side effect of aripiprazole, 
a new dopaminergic agent with reduced EPSE. Aripiprazole 
pharmacological mechanisms of action include D2 receptor 
binding, low anticholinergic properties and dopamine 
hypersensitivity (22-24). Furthermore, co-administration of 
Ziprasidone (antipsychotic) with sertraline (antidepressant) or 
the combination of lithium and risperidone induced 
RSsymptoms/signs (25,26). 
 
Rabbit Syndrome and Antidepressants 
 
Some clinical cases of RS were induced by Serotonin Specific 
Reuptake inhibitors (SSRI) such as citalopram, escitalopram or 
paroxetine with discontinuation leading to symptoms 
improvement (27,28).Cases of tricyclic antidepressant (TCA) 
dose-related RS symptoms were reported; responding to 
antiparkinsonian agents or propranolol (29). 
 
Pharmacology of the Medications Associated with rabbit 
syndrome 
 
RS affects only the buccal region, with the possible 
involvement of the basal ganglia; in particular the substantia 
nigra pars reticulate - also implicated in oral dyskinesia (30). 
RS could be due to imbalance of the cholinergic and 
dopaminergic neurotransmission in the basal ganglia similar to 
the antipsychotic induced parkinsonian syndrome (31), with 
cerebral scans supporting these ideas by revealinga decreased 
basal ganglia perfusion in the presence of RS (32). 
 
FGA such as haloperidol are dopamine (D2) receptors 
antagonists and block histamine, muscarinic and alpha-1 
receptors (33), while SGA such as quetiapine are serotonin-
dopamine antagonists (34).  Serotonin antagonism could 
increase dopaminergic neurotransmission in the nigrostriatal 
pathway, which reduces the risk of EPSE such as dystonic 
reactions, akathisia and tardive dyskinesia (34). TCAs inhibit 
serotonin and norepinephrine neurotransmitter reuptake by 
pre-synaptic neurons, increasing their levels in the synapse. 
TCA possess also high affinity to muscarinic, cholinergic and 
adrenergic receptors, while SSR Is inhibit serotonin reuptake 
in the brain. Anticholinergic such as trihexyphenidy l and 
procyclidine are used to counter the hyper-cholinergic state in 
RS (35). 
 
Management of Rabbit Syndrome 
 
RS may be due to a hyper-cholinergic state resulting from the 
blockade of dopaminergic neurons in the extrapyramidal 
system (35).  RS is easily treatable when recognized, but needs 
to be differentiated from tardive dyskinesia. Its treatment is 
empirical (7), with the first step to reduce/ stop the 
psychotropic medication. RS responded to anticholinergic 
drugs with the antipsychotic switch (36). Trihexyphenidyl as 
anticholinergic was used successfully in severe cases causing 
dysphagia (37,38) and in schizophrenic inpatients on long-term 
antipsychotics with a significant reduction in RS score and 
Simpson-Angus rating scale (31). Switching to a second 
generation antipsychotic with high anticholinergic properties, 
like olanzapine may be another possible management strategy 
as olanzapine has less risk to cause RS signs/symptoms 
compared to risperidone; however, care should be applied as 
some rare cases suggested that olanzapine itself could be a 
culprit (39,40). Quetiapine was effective as a mono-therapy for 
the management of both RS and psychotic symptoms (21). Use 
of an antiparkinsonian agent may be required (35,41), 
however, RS did not respond to levodopa or dopamine 
agonistsin some cases (42). 
 
DISCUSSION 
 
RS is a movement disorder affecting perioral muscles and has 
been traditionally associated mainly with first generation 
antipsychotics treatment. However, second generation 
antipsychotics such as risperidone and antidepressant 
medications could also be involved in the pathogenesis of RS. 
RS is considered a form of antipsychotic induced EPS 
Eoccurring late in treatment, even in the absence of other 
EPSE (18). RS differ from typical oral dyskinesia, where the 
tongue is involved and the movements could be suppressed 
voluntarily by the patient. This syndrome main management 
include reducing or stopping the culprit antipsychotic, while 
switching the medication and administering anticholinergic 
agents shown efficacy in reducing RS symptoms.  
 
As RS signs/symptoms highly resembles oral dyskinesia and 
tardive dyskinesia- conditions that could become worse upon 
administering of anticholinergic medications, it is imperative 
for psychiatrists and dentists to ensure that they could confirm 
RS before starting treatment. 
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